Appointment of Architectural Design Team for The Fleming Centre, St Mary's Hospital, London

Descriptions

Imperial College Healthcare NHS Trust (“ICHT”, the "Authority") is issuing this invitation for the procurement and appointment of an Architectural Design Team for The Fleming Centre, St Mary’s Hospital, London.This procurement will be run via a Competitive with Negotiation procedure under the Public Contracts Regulations 2015 ("PCR").The purpose of this procurement exercise is for the Imperial College Healthcare NHS Trust (ICHT) to appoint an architectural design team to provide architectural and supporting specialist design services covering RIBA Stages 2-7 for their Fleming Centre project located at The Bays site, St Mary’s Hospital, London.The Fleming Centre, a collaborative initiative between the Imperial College Healthcare NHS Trust (ICHT) and the Imperial College London (ICL), will be a major new contributor to the UK’s vision that by 2040 antimicrobial resistance (AMR) will be effectively contained, controlled, and mitigated. It will be a place of discovery, innovation and, above all, the place that drives global change, from the birthplace of antibiotics at St. Mary’s Hospital, where Sir Alexander Fleming first discovered penicillin. High-profile work by the Trust and College, throughout the Covid-19 pandemic has transformed the value of university and clinical research on infection, and the application of this research in acute care. To do this effectively, the Centre will combine three major strands of activity: •world class scientific and clinical research;•on-site public engagement; and•convening power and policy work relating to behaviour change. The project is expected to be completed by Q1 2029, with an opening and ‘soft launch’ in Q4 2028, coinciding with the centenary of Fleming’s discovery of penicillin. The anticipated build cost for the project is £30,000,000, with a contract term of four (4) years. The Fleming Centre will be of national and international importance as a hub for antimicrobial research (AMR), policy development and public engagement. It will be a major new contributor to the UK’s vision that by 2040 AMR will be effectively contained, controlled, and mitigated. It will be a place of discovery, innovation and, above all, the place that drives global change, from the birthplace of antibiotics.